MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent

Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has received a Certificate of Grant in India for its respiratory illness and preventive care technology patent. The patent, valid until March 16, 2040, covers a proprietary formulation designed to combat infections including colds, respiratory diseases, and orally transmitted infections like HPV. This follows MangoRx's acquisition of Intramont Technologies' global patent portfolio on April 24, 2024.

The technology uses an orally available solution containing GALALCOOL®️, zinc protoporphyrin IX, and select tannins to inhibit various pathogens. MangoRx and Intramont have initiated clinical trials in India to demonstrate the formulation's efficacy in preventing respiratory illnesses, with results expected later this quarter. The company is also considering expanding trials to address avian influenza concerns.

Positive

• Received Certificate of Grant in India for respiratory illness and preventive care technology patent
• Patent valid until March 16, 2040, providing long-term protection
• Acquired comprehensive global patent portfolio from Intramont Technologies
• Initiated clinical trials in India to demonstrate efficacy in preventing respiratory illnesses
• Potential expansion of trials to address avian influenza concerns

Negative

• None.

Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has received a Certificate of Grant and recordal of patent under section 43 of the Patents Act in respect of patent application no. 202117034253 with the Government of India, originally applied for by Intramont Technologies, Inc. (“Intramont”).

The duration of the patent granted in India is twenty (20) years from the effective filing date of the application, or until March 16, 2040.

This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies. The Certificate of Grant covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus (HPV). The US patent (Patent 11,517,523) was initially applied for by Intramont and subsequently acquired by MangoRx on April 24, 2024, further expanding the global protection for its groundbreaking preventive care technology.

Jacob Cohen, Co-Founder and CEO of MangoRx, expressed his enthusiasm about this achievement: “Receiving this Certificate of Grant in India is a critical step in our global strategy to protect and commercialize our innovative preventive care technology. It underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience. This patent not only fortifies our intellectual property but also paves the way for introducing our cutting-edge products to the market in India.”

The patented technology is designed to prevent illnesses acquired through the oral cavity and pharynx using an orally available solution, such as toothpaste, oral dissolvable tablets (ODT), lozenges, or mouthwash. The unique formulation features GALALCOOL^®️, zinc protoporphyrin IX, and select tannins, which work synergistically to inhibit various pathogens, offering comprehensive protection against oral and respiratory infections.

In parallel with this patent grant, MangoRx and Intramont have initiated clinical trials for this technology, collaborating with Vipragen Biosciences in India. These trials aim to demonstrate the efficacy of the formulation in preventing respiratory illnesses, with results expected later this quarter. The study focuses on evaluating the technology’s prophylactic performance against select viral strains, including H1N1, with the potential to expand into further trials involving the H5N1 strain to address concerns related to avian influenza outbreaks.

This expansion aligns with MangoRx’s mission to enhance well-being through innovative health solutions. The Certificate of Grant in India joins an already robust portfolio of U.S. and international patents, including its recent patent grants in Australia and Japan, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement and other continued listing requirements of Nasdaq; the Company’s stockholders’ equity as of the Company’s next fiscal quarter end, which is required to be above $2.5 million pursuant to correspondence from Nasdaq; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

FAQ

What patent did MangoRx (MGRX) receive in India?

MangoRx (MGRX) received a Certificate of Grant in India for its respiratory illness and preventive care technology patent, valid until March 16, 2040.

What does MangoRx's (MGRX) patented technology aim to prevent?

MangoRx's (MGRX) patented technology aims to prevent illnesses acquired through the oral cavity and pharynx, including common colds, respiratory diseases, and orally transmitted infections like HPV.

What are the key components of MangoRx's (MGRX) patented formulation?

MangoRx's (MGRX) patented formulation includes GALALCOOL®️, zinc protoporphyrin IX, and select tannins, which work together to inhibit various pathogens.

Where is MangoRx (MGRX) conducting clinical trials for its preventive care technology?

MangoRx (MGRX) is conducting clinical trials for its preventive care technology in India, collaborating with Vipragen Biosciences.